Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Registration Trial

• Status: Not yet recruiting
• Trial end date: 2030-07-01

Summary

This ComboMATCH registration trial studies how well treatment that is directed by genetic testing works in treating patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

• Phase: Phase 2

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Albumin-Bound Paclitaxel; Fluorouracil; Fulvestrant; Leucovorin; Olaparib; Oxaliplatin; Paclitaxel; Palbociclib